

A Novel Micelleplex for Tumour-Targeted Delivery of CRISPR-Cas9 against KRAS-Mutated Lung Cancer

Siyu Chen,^a Mariem Triki,^a Simone Pinto Carneiro,^a and Olivia Monika Merkel^{*a}
^a Ludwig-Maximilians-University, Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Butenandtstraße 5-13, Munich, 81377, Germany




Figure S1. eGFP mRNA expression with C14-PEI at different modification level in A549 cells. A) Median eGFP fluorescence intensity after transfection 24h, results are normalised fold change; **B)** the percentage of eGFP positive cells.




Figure S2. eGFP mRNA expression with 33% C14-PEI at different mass ratios in A549 cells. A) Median eGFP fluorescence intensity after transfection 24h; **B)** the percentage of eGFP positive cells.




Figure S3. GPC analysis of 33% C14-PEI before purification.




Figure S4. Characterization of C14-PEI micelleplexes co-loaded with Cas9 mRNA and sgRNA. **A)** the hydrodynamic diameter (bars) and polydispersity index (PDI, dots) of micelleplexes (n=3); **B)** the zeta potential of micelleplexes (n=3).